Spyglass Pharma
NASDAQ: SGPAliso Viejo, US · Founded 2019 · 77 employees on LinkedIn · 4 known investors
SpyGlass Pharma develops a sustained drug delivery platform for treating chronic ophthalmic diseases such as glaucoma, integrating drugs, procedures, and devices for long-term disease control and vision preservation. It serves the ophthalmic care market, spanning discovery through late-stage clinical development and commercialization.
Founders & leadership
Spyglass Pharma was founded in 2019 by Malik Kahook, Glenn Sussman, and Malik Y. Kahook.
MK
Malik KahookCo-founder
GS
Glenn SussmaninCo-Founder and CTO
MY
Malik Y. KahookCo-founder
PM
Patrick MooneyCEO
Board
JM
Jake MerrillBoard director
GP
Geoff PardoBoard director
BK
Bilal KhanBoard director
CY
Cynthia YeeBoard director
RZ
Roger ZhangBoard director
AB
ZS
Zach ScheinerBoard director
Investors · 4
Reported raises · per SEC filings
Form D private placements$134.8M disclosed across 4 rounds · 2019–2025
▶$75MraisedJun 2025 · 10 investors · Other Health CareRule 506(b)
▶$75MraisedJun 2025 · 10 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Jake MerrillDirector
- Malik KahookExecutive Officer, Director
- Geoff PardoDirector
- Bilal KhanDirector
- Cynthia YeeDirector
- Roger ZhangDirector
- Patrick MooneyExecutive Officer, Director
- Ali BehbahaniDirector
- Zach ScheinerDirector
- Offering amount
- $75M
- Amount sold
- $75M
- First sale
- May 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$40MraisedJul 2023 · 7 investors · Other Health CareRule 506(b)
▶$40MraisedJul 2023 · 7 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Ali BehbahaniDirector
- Patrick MooneyExecutive Officer, Director
- Cynthia YeeDirector
- Malik KahookExecutive Officer, Director
- Roger ZhangDirector
- Zach ScheinerDirector
- Offering amount
- $90M
- Amount sold
- $40M
- First sale
- Jul 2023
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$13.7MraisedJan 2021 · 4 investors · Other Health CareRule 506(b)
▶$13.7MraisedJan 2021 · 4 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Kirk NielsenDirector
- Malik KahookExecutive Officer, Director
- Ali BehbahaniDirector
- Tak CheungDirector
- Cynthia YeeDirector
- Glenn SussmanExecutive Officer, Director
- Offering amount
- $37.5M
- Amount sold
- $13.7M
- First sale
- Dec 2020
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$6MraisedJun 2019 · 2 investors · Other Health CareRule 506(b)
▶$6MraisedJun 2019 · 2 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Malik KahookExecutive Officer, Director
- Ali BehbahaniDirector
- Glenn SussmanExecutive Officer, Director
- Offering amount
- $6M
- Amount sold
- $6M
- First sale
- May 2019
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 2
by search overlapOis20 shared keywordsOIS is a conference and community, active since 2009, focused on eye care and ophthalmology innovation, connecting startups, strategics, investors, and clinicians. It provides curated programming, networking, and access to new technologies in the ophthalmology industry.
Tenpoint Therapeutics12 shared keywordsTenpoint Therapeutics develops treatments for age-related ophthalmic conditions, with an initial focus on presbyopia care for the aging eye. The company works with eye care professionals to advance therapies in the ophthalmology market.
Companies competing with Spyglass Pharma for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Spyglass Pharma do?
- SpyGlass Pharma develops a sustained drug delivery platform for treating chronic ophthalmic diseases such as glaucoma, integrating drugs, procedures, and devices for long-term disease control and vision preservation. It serves the ophthalmic care market, spanning discovery through late-stage clinical development and commercialization.
- Who founded Spyglass Pharma?
- Spyglass Pharma was founded by Malik Kahook, Glenn Sussman, Malik Y. Kahook in 2019.
- Who are Spyglass Pharma's investors?
- Spyglass Pharma's investors include New Enterprise Associates (NEA), RA Capital, Samsara BioCapital, Vensana Capital.
- How much funding has Spyglass Pharma raised?
- Spyglass Pharma has disclosed $134.8M raised across 4 rounds.
- Where is Spyglass Pharma headquartered?
- Spyglass Pharma is headquartered in Aliso Viejo, US.